Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Myriad is a biotechnology company focused on molecular diagnostics and therapeutic drug development. Its operations are divided into three segments: Research, Molecular Diagnostics, and Drug Development. The company has not yet attained profitability and relies on cash reserves and financing activities to fund operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2008 | Nine Months Ended Mar 31, 2008 |
|---|---|---|
| Total Revenue | $61,765 | $166,773 |
| Molecular Diagnostic Revenue | $59,023 | $158,176 |
| Net Loss | $(4,631) | $(17,696) |
| Operating Loss | $(7,816) | $(28,133) |
| Loss Per Share (Basic & Diluted) | $(0.10) | $(0.40) |
| Cash and Cash Equivalents (End of Period) | $142,392 | $142,392 |
| Total Marketable Investment Securities | $168,096 | $168,096 |
| Accumulated Deficit | $(270,096) | $(270,096) |
Liquidity: As of March 31, 2008, the company held approximately $310.5 million in cash, cash equivalents, and marketable investment securities. Management believes these resources are sufficient to fund operations for at least the next two years.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 51% for the three months and 49% for the nine months ended March 31, 2008, compared to the prior year periods. This was driven primarily by a 55% increase in molecular diagnostic revenue (three months) and 54% increase (nine months), attributed to expanded sales forces and direct-to-consumer marketing for the BRACAnalysis product.
- Expense Increases:
- R&D Expenses: Increased 36% (three months) and 14% (nine months) due to higher costs for pharmaceutical development programs (specifically Flurizan) and increased share-based compensation.
- Selling, General, and Administrative (SG&A): Increased 54% (three months) and 74% (nine months). Drivers included expanded sales/marketing efforts, bad debt expense increases related to sales growth, and commercialization preparations for Flurizan.
- Net Loss Improvement: Despite higher expenses, the net loss narrowed to $4.6 million for the quarter (from $5.9 million) and $17.7 million for the nine months (from $27.2 million), aided by significant interest income ($3.3 million and $10.8 million, respectively).
- Cash Flow: Net cash used in operating activities improved significantly to $8.1 million for the nine months ended March 31, 2008, compared to $26.1 million used in the prior year period.
Guidance, Outlook, and Risks
- Clinical Trial Milestones: The company anticipates reporting top-line results for the U.S. Phase 3 trial of Flurizan (Alzheimer's treatment) in June 2008. The international Phase 3 trial is scheduled to conclude in October 2008.
- Future Revenue: If Flurizan receives regulatory approval, the company anticipates revenues could commence in mid-to-late 2009. No specific revenue guidance was provided for other drug candidates due to early-stage development.
- Acquisition: On April 10, 2008, Myriad acquired NaturNorth Technologies, LLC for approximately $1.35 million in cash to acquire key technology. This is not expected to have a material immediate impact on results.
- Risks and Contingencies:
- Clinical Trial Outcomes: Future success depends heavily on the results of ongoing clinical trials for Flurizan, Azixa, and other candidates. Failure to meet efficacy or safety endpoints could halt development.
- Regulatory Approval: No assurance exists that the FDA or other authorities will approve any drug candidates.
- Market Acceptance: Success depends on market acceptance of molecular diagnostic products and potential new therapeutics.
- Capital Requirements: While current funds are adequate for two years, the company may need to raise additional capital if clinical trials extend or if commercialization costs exceed estimates.
Investor Verification Checklist
- Flurizan Trial Results: Verify the timing and outcome of the U.S. Phase 3 trial results expected in June 2008, as this is the primary catalyst for future drug revenue.
- Bad Debt Trends: Monitor the allowance for doubtful accounts, which increased to $3.95 million, and the associated bad debt expense ($8.3 million for the nine months), to assess collection risks as sales volume grows.
- Share-Based Compensation: Review the impact of share-based compensation ($10.6 million for the nine months), which significantly impacts operating expenses and dilution.
- Investment Portfolio: Confirm the status of auction rate securities held in the investment portfolio, noting that auctions have been failing since February 2008, though management deems the impact immaterial.
- Capital Sufficiency: Assess whether the $310.5 million in liquid assets will remain sufficient given the high burn rate associated with Phase 3 trials and commercialization preparations.